We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeted Therapies for Malignant Glioma: Progress and Potential.
- Authors
Mercer, Ronald W.; Tyler, Matthew A.; Ulasov, Ilya V.; Lesniak, Maciej S.
- Abstract
Malignant gliomas represent one of the most aggressive forms of brain cancer. Recent advances in the understanding of the deregulated molecular pathways of gliomas have brought about targeted therapies that have the ability to increase therapeutic efficacy in tumors while decreasing toxicity. Multi-targeted kinks inhibitors, novel mono clonal antibodies, and new vaccines have been developed. Standard treatments and current development of new therapies for malignant gliomas are reviewed, focusing specifically on growth factors and their receptors (e.g. epidermal growth factor receptor, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor), as well as the intracellular effector molecules that are downstream of these growth factors (e.g. Ras/Raf/mitogen-activated protein kinase, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin, and protein kinase C). The efficacies of other novel targeted inhibitors such as deacetylase inhibitors and heat shock protein 90 inhibitors in the treatment of gliomas are also discussed, as well as new combination therapies. In order for new agents to increase treatment efficacy, new targets need to be developed, drug delivery efficiency needs to be improved, and new biomarkers need to be discovered. All of these goals can be accomplished with time through innovative experimental designs.
- Subjects
CYTOKINES; GLIOMAS; NERVOUS system tumors; ASTROCYTOMAS; BLOOD proteins
- Publication
BioDrugs, 2009, Vol 23, Issue 1, p25
- ISSN
1173-8804
- Publication type
Article
- DOI
10.2165/00063030-200923010-00003